drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (gene-modified T cells; CAR T cells)
drug_description
Autologous patient T cells genetically engineered to express an anti-CD19 chimeric antigen receptor; targeting CD19+ B cells and plasmablasts to reduce AQP4-IgG autoantibody production in NMOSD.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with an anti‑CD19 chimeric antigen receptor recognize CD19 on B cells and plasmablasts, triggering T‑cell activation and cytotoxic killing (perforin/granzyme) to deplete the B‑cell lineage and reduce pathogenic AQP4‑IgG autoantibody production in NMOSD.
drug_name
Autologous CD19-directed CAR-T cells
nct_id_drug_ref
NCT05828212